rp 73401 has been researched along with rolipram in 42 studies
| Studies (rp 73401) | Trials (rp 73401) | Recent Studies (post-2010) (rp 73401) | Studies (rolipram) | Trials (rolipram) | Recent Studies (post-2010) (rolipram) |
|---|---|---|---|---|---|
| 92 | 0 | 23 | 1,604 | 17 | 401 |
| 92 | 0 | 23 | 26 | 0 | 15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (38.10) | 18.2507 |
| 2000's | 21 (50.00) | 29.6817 |
| 2010's | 4 (9.52) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ashton, MJ; Cook, DC; Fenton, G; Karlsson, JA; Palfreyman, MN; Raeburn, D; Ratcliffe, AJ; Souness, JE; Thurairatnam, S; Vicker, N | 1 |
| Bordner, J; Campbell, E; Cheng, JB; Cohan, VL; DiCapua, FM; Giordano, LA; Hibbs, TA; Jenkinson, TH; Kleinman, EF; Pettipher, ER; Salter, ED; Shirley, JT | 1 |
| Andresen, CJ; Cheng, JB; Cohan, VL; Decker, C; DiCapua, FM; Duplantier, AJ; Johnson, KL; Kraus, KG; Turner, CR; UmLand, JP; Watson, JW; Wester, RT; Williams, AS; Williams, JA | 1 |
| Djuric, S; Hanney, B; He, W; Huang, FC; Liang, G; Mason, J; Miller, B; Souness, J | 1 |
| Cox, P; Djuric, SW; Huang, FC; Hulme, C; Labaudiniere, R; Mathew, R; Miller, B; Moriarty, K; Page, KM; Ramanjulu, M; Souness, J; Travis, J; Uhl, J | 1 |
| Cox, P; Djuric, SW; Huang, F; Hulme, C; Labaudiniere, R; Mathew, R; Miller, B; Moriarty, K; Page, KM; Ramanjulu, M; Souness, J; Travis, J; Uhl, J | 1 |
| Ferlenga, P; Marchini, F; Morazzoni, G; Napoletano, M; Norcini, G; Pellacini, F; Pradella, L | 2 |
| Fattori, R; Ferlenga, P; Marchini, F; Morazzoni, G; Napoletano, M; Norcini, G; Pellacini, F; Pradella, L | 1 |
| Alonso, JM; Andrés, JI; Boeckx, G; Cools, M; de Chaffoy, D; De Clerck, F; Deroose, F; Díaz, A; Diels, G; Fernández, J; Freyne, EJ; Iturrino, L; Martínez, P; Matesanz, E; Megens, A; Peeters, D; Petit, D; Somers, M; Stoppie, P; Van Wauwe, J | 1 |
| Ikezawa, K; Kikkawa, H; Kuroda, T; Naito, K; Nakata, A; Sugahara, M; Terakawa, Y; Ukita, T; Wada, K | 1 |
| Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
| Bachert, EL; Cheng, JB; Cohan, VL; Duplantier, AJ; Jenkinson, TH; Kraus, KG; McKechney, MW; Pillar, JD; Watson, JW | 1 |
| Barlow, DJ; Ehrman, TM; Hylands, PJ | 1 |
| Ashton, TD; Bland, ND; Campbell, RK; Cotter, K; Fang, AP; Gangurde, R; Garceau, N; Gechijian, L; Gustafson, AE; McAllister, G; Ochiana, SO; Ondrechen, MJ; Ortenberg, R; Pollastri, MP; Tallman, C; Wang, C; Wang, Z | 1 |
| de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R | 1 |
| Hatzelmann, A; Schudt, C; Tenor, H | 1 |
| Ashton, MJ; Foster, M; Karlsson, JA; Maslen, C; Palfreyman, MN; Raeburn, D; Souness, JE; Webber, S | 1 |
| Battram, CH; Jordan, R; Lewis, SA; Raeburn, D; Sharma, S; Souness, JE; Tomkinson, A; Underwood, SL; Webber, SE; Woodman, VR | 1 |
| Ebsworth, K; Griffin, M; Karlsson, JA; Maslen, C; Palfreyman, MN; Pollock, K; Scott, LC; Souness, JE | 1 |
| Alexander, R; Allen, R; Blease, K; Bloxham, D; Boyd, E; Catterall, C; Eaton, M; Gozzard, N; Head, J; Higgs, G; Holbrook, M; Howat, D; Hughes, B; Hughes, P; James, T; Kingaby, R; Lisle, H; Lumb, S; Merriman, M; Owens, R; Perry, M; Russell, A; Smith, B; Wales, M; Warrellow, G | 1 |
| Gozzard, N; Higgs, G; Holbrook, M; Hughes, B; James, T | 1 |
| Burman, M; Jacobitz, S; Livi, GP; McLaughlin, MM; Torphy, TJ | 1 |
| Au, BT; Collins, PD; Teixeira, MM; Williams, TJ | 1 |
| Cooper, N; Gristwood, RW; Hellewell, PG; Macari, DM; Miotla, JM; Teixeira, MM; Warneck, J; Wills, RE | 1 |
| Ferré, F; Leroy, MJ; Méhats, C; Paris, B; Pernin, N; Robert, B; Tanguy, G | 1 |
| Arányi, P; Baranyi, A; Bence, J; Boronkay, E; Kapui, Z; Mikus, E; Urbán Szabó, K | 1 |
| Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL | 1 |
| Buckley, G; Cooper, N; Dyke, HJ; Galleway, F; Gowers, L; Gregory, JC; Hannah, DR; Haughan, AF; Hellewell, PG; Kendall, HJ; Lowe, C; Maxey, R; Montana, JG; Naylor, R; Picken, CL; Runcie, KA; Sabin, V; Tuladhar, BR; Warneck, JB | 1 |
| Branscheid, D; Dent, G; Magnussen, H; Rabe, KF; Rühlmann, E; Schmidt, DT; Watson, N | 1 |
| Ezeamuzie, CI | 1 |
| Belleguic, C; Boichot, E; Corbel, M; Germain, N; Lagente, V | 1 |
| Alves, AC; Barreto, EO; Cordeiro, RS; Jose, PJ; Lagente, V; Martins, MA; Pires, AL; Serra, MF; Silva, JP; Silva, PM; Teixeira, MM | 1 |
| O'Donnell, JM; Zhang, HT; Zhao, Y | 2 |
| Chen, JC; Chen, JQ; Xie, QM; Zhu, YL | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Akuta, K; Hirose, R; Ichimura, M; Manabe, H; Nonaka, H; Ohshima, E; Sato, S; Yanagawa, K | 1 |
| de Visser, YP; Laghmani, EH; Nieuwland, K; van Wijngaarden, S; Wagenaar, GT; Walther, FJ | 1 |
| Jonas, U; Kedia, G; Knapp, WH; Scheller, F; Sormes, M; Stief, CG; Uckert, S | 1 |
| Kedia, GT; Kuczyk, MA; Merseburger, AS; Polat, H; Ückert, S | 1 |
| Abou Saleh, L; Aragon, IV; Boyd, A; Koloteva, A; McDonough, W; Murphy, JM; Rich, J; Richter, W | 1 |
42 other study(ies) available for rp 73401 and rolipram
| Article | Year |
|---|---|
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta; Asthma; Benzamides; Bronchial Spasm; Eosinophils; Guinea Pigs; Histamine; Isoenzymes; Kinetics; Male; Molecular Structure; Phosphodiesterase Inhibitors; Pyridines; Structure-Activity Relationship; Superoxides; Swine | 1994 |
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Hydroxamic Acids; Models, Chemical; Molecular Structure; Phosphodiesterase Inhibitors; Pyrrolidinones; Rolipram; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 1998 |
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
Topics: Airway Obstruction; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Cell Line; Cyclic AMP; Cytokines; Dihydropyridines; Drug Evaluation, Preclinical; Eosinophils; Guinea Pigs; Humans; In Vitro Techniques; Isoenzymes; Macaca fascicularis; Molecular Conformation; Neutrophils; Ovalbumin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazoles; Pyrrolidinones; Rolipram; Structure-Activity Relationship | 1998 |
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Brain; Cyclic Nucleotide Phosphodiesterases, Type 4; Dogs; Endotoxemia; Female; Guinea Pigs; In Vitro Techniques; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Phosphodiesterase Inhibitors; Pyridines; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Vomiting | 1998 |
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Biological Availability; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Evaluation; Indoles; Mice; Phosphodiesterase Inhibitors; Pyrrolidinones; Rolipram; Structure-Activity Relationship | 1998 |
Orally active indole N-oxide PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Arthritis, Infectious; Cyclic Nucleotide Phosphodiesterases, Type 4; Dogs; Female; Indoles; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Tumor Necrosis Factor-alpha | 1998 |
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Phthalazines; Pyridines; Rolipram | 2000 |
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Biological Availability; Cyclic Nucleotide Phosphodiesterases, Type 4; Enzyme Inhibitors; Guinea Pigs; Humans; Inhibitory Concentration 50; Molecular Structure; Monocytes; Neutrophils; Phthalazines; Protein Binding; Pyridines; Rolipram; Tumor Necrosis Factor-alpha | 2001 |
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Drug Evaluation, Preclinical; Humans; Hydrogen Bonding; Neutrophils; Phosphodiesterase Inhibitors; Phthalazines; Rolipram; Structure-Activity Relationship | 2002 |
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dose-Response Relationship, Drug; Ear Diseases; Enzyme Inhibitors; Humans; Imidazoles; Inflammation; Inhibitory Concentration 50; Rats; Structure-Activity Relationship | 2002 |
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Binding, Competitive; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Indicators and Reagents; Isoquinolines; Kinetics; Lipopolysaccharides; Mice; Phosphodiesterase Inhibitors; Quinolines; Rolipram; Stereoisomerism; Tumor Necrosis Factor-alpha | 2003 |
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Biological Availability; Cyclic Nucleotide Phosphodiesterases, Type 4; Dogs; Eosinophils; Female; Ferrets; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Isoenzymes; Male; Phosphodiesterase Inhibitors; Pyrazoles; Pyridines; Rats; Recombinant Proteins; Structure-Activity Relationship; Triazoles; Vomiting | 2007 |
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2010 |
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Catalytic Domain; Humans; Models, Molecular; Molecular Structure; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2011 |
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2016 |
Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Benzamides; Blood Proteins; Cell Separation; Complement C5a; Cyclic Nucleotide Phosphodiesterases, Type 4; Electromagnetic Fields; Eosinophil Granule Proteins; Eosinophil-Derived Neurotoxin; Eosinophils; Humans; Inflammation Mediators; Luminescent Measurements; Naphthyridines; Neurotoxins; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Pyridines; Pyrrolidinones; Ribonuclease, Pancreatic; Ribonucleases; Rolipram; Theophylline | 1995 |
Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta; Base Sequence; Benzamides; Blood Proteins; Cattle; Cyclic AMP; DNA Primers; Eosinophil Granule Proteins; Eosinophils; Glutathione; Guinea Pigs; Male; Methacholine Chloride; Molecular Sequence Data; Muscle Contraction; Muscle, Smooth; Protein Binding; Pyridines; Pyrrolidinones; Ribonucleases; Rolipram; Superoxides; Swine; Vanadates | 1995 |
Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Topics: Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchial Hyperreactivity; Bronchial Spasm; Bronchodilator Agents; Capillary Permeability; Guinea Pigs; Hemodynamics; Histamine; Inflammation; Male; Muscle Contraction; Muscle, Smooth; Phosphodiesterase Inhibitors; Platelet Activating Factor; Pyridines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Rolipram | 1994 |
Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Topics: Benzamides; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Lipopolysaccharides; Monocytes; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Rolipram; Tumor Necrosis Factor-alpha | 1996 |
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Analysis of Variance; Animals; Asthma; Benzamides; Bronchoconstriction; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dose-Response Relationship, Drug; Eosinophilia; Guinea Pigs; Humans; Interleukin-5; Isoenzymes; Lung; Male; Neutrophils; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridines; Pyrrolidinones; Rabbits; Rats; Rolipram | 1996 |
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Topics: Analysis of Variance; Animals; Benzamides; Bronchial Hyperreactivity; Bronchoconstriction; Carbachol; Cricetinae; Disease Models, Animal; Enzyme Inhibitors; Guinea Pigs; Histamine Antagonists; In Vitro Techniques; Lung; Male; Muscle Contraction; Muscle Relaxation; Parasympathomimetics; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Rolipram; Trachea; Vagus Nerve | 1996 |
Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Base Sequence; Benzamides; Binding Sites; Binding, Competitive; Catalysis; Cyclic Nucleotide Phosphodiesterases, Type 4; Kinetics; Molecular Sequence Data; Peptide Mapping; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary; Pyridines; Pyrrolidinones; Recombinant Proteins; Rolipram; Structure-Activity Relationship; Tritium | 1996 |
Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Albuterol; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Drug Synergism; Humans; Interleukin-8; Neutrophils; Nitriles; Phosphodiesterase Inhibitors; Prostaglandins; Pyridines; Pyrrolidinones; Rolipram; Zymosan | 1998 |
A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Dermatitis; Eosinophils; Female; Guinea Pigs; Humans; Macrophages; Male; Neutrophils; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Rolipram; Skin | 1999 |
Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Female; Humans; Immunoblotting; In Vitro Techniques; Muscle Relaxation; Myometrium; Phosphodiesterase Inhibitors; Pregnancy; Pyridines; Rolipram; Uterine Contraction | 2000 |
Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Binding, Competitive; Catalytic Domain; Cyclic Nucleotide Phosphodiesterases, Type 4; Papaverine; Parasympatholytics; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Tritium | 1999 |
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Budesonide; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dextrans; Disease Models, Animal; Enzyme Inhibitors; Eosinophil Peroxidase; Eosinophils; Fluticasone; Glucocorticoids; Guinea Pigs; Inflammation; Lung; Male; Ovalbumin; Peroxidases; Pyridines; Rats; Rats, Sprague-Dawley; Rolipram | 2000 |
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Asthma; Benzamides; Benzofurans; Cyclic Nucleotide Phosphodiesterases, Type 4; Eosinophilia; Guinea Pigs; Inhibitory Concentration 50; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Structure-Activity Relationship; Vomiting | 2000 |
The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Antigens, Dermatophagoides; Benzamides; Bronchi; Bronchodilator Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Glycoproteins; Histamine; Humans; In Vitro Techniques; Leukotriene C4; Lung Neoplasms; Muscle Contraction; Phosphodiesterase Inhibitors; Pyridazines; Pyridines; Rolipram; Theophylline | 2000 |
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Adult; Albuterol; Benzamides; Cell Degranulation; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Eosinophil Peroxidase; Eosinophils; Histamine; Humans; Nitriles; Peroxidases; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Superoxides; Theophylline | 2001 |
Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Bucladesine; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; N-Formylmethionine Leucyl-Phenylalanine; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Superoxides; Time Factors | 2001 |
Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Albuterol; Allergens; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cell Adhesion; Cell Degranulation; Cell Movement; Chemokine CCL11; Chemokines, CC; Chemotaxis, Leukocyte; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dose-Response Relationship, Drug; Eosinophils; Female; Guinea Pigs; Immune Sera; Isoenzymes; Isoquinolines; Male; Mast Cells; Ovalbumin; Phosphodiesterase Inhibitors; Pleurisy; Pyridines; Rats; Rats, Wistar; Rolipram; Tetrahydroisoquinolines | 2001 |
Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzamides; Binding Sites; Brain; Cerebral Cortex; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytosol; In Vitro Techniques; Magnesium; Male; Membranes; Phosphodiesterase Inhibitors; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rolipram | 2003 |
Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function.
Topics: Animals; Antidepressive Agents; Benzamides; Binding Sites; Brain; Cell Membrane; Cerebral Cortex; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Hippocampus; Male; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic; Receptors, Serotonin; Rolipram; Time Factors; Tritium | 2003 |
Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Indomethacin; Phosphodiesterase Inhibitors; Purinones; Pyridines; Rolipram; Saccharomyces cerevisiae | 2004 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Topics: Animals; Benzamides; Binding Sites; Binding, Competitive; Brain; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Kinetics; Male; Molecular Structure; Naphthyridines; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rolipram; Shrews; Tritium; Vomiting; Xanthines | 2007 |
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Topics: Animals; Animals, Newborn; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Expression Profiling; Humans; Infant, Newborn; Inflammation; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Alveoli; Pulmonary Fibrosis; Pyridines; Rats; Rats, Wistar; Respiration, Artificial; Respiratory Distress Syndrome; Rolipram | 2008 |
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Topics: Aged; Benzamides; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; In Vitro Techniques; Male; Middle Aged; Norepinephrine; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostate; Purines; Pyridines; Rolipram; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Aged; Benzamides; Colforsin; Cyclic AMP; Humans; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Papaverine; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostate; Purines; Pyridines; Rolipram; Signal Transduction; Sildenafil Citrate; Sulfones | 2012 |
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Female; Gastroparesis; Mice; Mice, Nude; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidinones; Rolipram | 2020 |